PsiOxus Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev

OXFORD, UK – 16 December 2015 PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, has initiated a study to assess the safety and efficacy of a therapy combining Merck’s Keytruda® (pembrolizumab)… read more →